{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatoses&page=72",
    "query": {
      "condition": "Dermatoses",
      "page": 72
    },
    "page_size": 10
  },
  "pagination": {
    "page": 72,
    "page_size": 10,
    "total_count": 13610,
    "total_pages": 1361,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatoses&page=73&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatoses&page=71&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T08:15:22.268Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00293891",
      "title": "A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 658,
      "start_date": null,
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2007-12-24",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00293891"
    },
    {
      "nct_id": "NCT04822597",
      "title": "Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Sentinel Lymph Node",
        "Breast Neoplasms",
        "Breast Cancer Female"
      ],
      "interventions": [
        {
          "name": "Lidocaine patch",
          "type": "DRUG"
        },
        {
          "name": "Buzzy(R)",
          "type": "DEVICE"
        },
        {
          "name": "Ice pack",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 167,
      "start_date": "2021-04-23",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04822597"
    },
    {
      "nct_id": "NCT00232479",
      "title": "Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab, docetaxel and carboplatin in dose dense regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2005-09",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2012-08-21",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00232479"
    },
    {
      "nct_id": "NCT07186296",
      "title": "EXoPERT EMERALD Clinical Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Colon Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "EXoPred",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "EXoPERT",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 1400,
      "start_date": "2025-05-09",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 9,
      "location_summary": "Long Beach, California • Los Angeles, California • Honolulu, Hawaii + 6 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07186296"
    },
    {
      "nct_id": "NCT05366855",
      "title": "Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Pustular Psoriasis"
      ],
      "interventions": [
        {
          "name": "Double-blind 200 mg imsidolimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Open-label 200 mg imsidolimab",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "OTHER"
        },
        {
          "name": "Imsidolimab 750 mg IV/200 mg SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-04-21",
      "completion_date": "2024-07-12",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 5,
      "location_summary": "Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Springville",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05366855"
    },
    {
      "nct_id": "NCT02425826",
      "title": "A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parapsoriasis"
      ],
      "interventions": [
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo-Apremilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2015-04-20",
      "completion_date": "2016-11-22",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Fremont, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02425826"
    },
    {
      "nct_id": "NCT01969643",
      "title": "A Safety Study of SGN-LIV1A in Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Positive Breast Neoplasms",
        "Hormone Receptor Positive Breast Neoplasms",
        "Triple Negative Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "ladiratuzumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 290,
      "start_date": "2013-10-22",
      "completion_date": "2023-02-04",
      "has_results": false,
      "last_update_posted_date": "2023-03-07",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01969643"
    },
    {
      "nct_id": "NCT02548689",
      "title": "PAI-1 Expression in Non-scarring Hair Loss",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Androgenetic Alopecia",
        "Telogen Effluvium",
        "Alopecia Areata"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-07",
      "completion_date": "2021-06",
      "has_results": false,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548689"
    },
    {
      "nct_id": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fentanyl sublingual spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 1,
      "location_summary": "Chandler, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538850"
    },
    {
      "nct_id": "NCT07216274",
      "title": "Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "QT Ultrasound Breast Scanner",
          "type": "DEVICE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2025-07-31",
      "completion_date": "2025-10-20",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-04T08:15:22.268Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07216274"
    }
  ]
}